Cannabidiol (CBD) is an effective, safe, and easy to administer adjunct treatment option for glioblastoma, according to a new study published by the U.S. National Institute of Health.
According to the study’s researchers, glioblastoma (GBM) “is the most common invasive brain tumor composed of diverse cell types with poor prognosis.” Given the ineffectiveness of current standard therapies (surgery, radiotherapy, and concomitant chemotherapy) in managing patients with GBM, they say “it is necessary to develop new ways of treating these lethal brain tumors.”
The study states that “Given the potential therapeutic effects of cannabidiol (CBD) in a wide spectrum of diseases, including malignancies, we tested, for the first time, whether inhalant CBD can inhibit GBM tumor growth using a well-established orthotopic murine model.”
Optical imaging, histology, immunohistochemistry, and flow cytometry were employed to describe the outcomes such as tumor progression, cancer cell signaling pathways, and the TME (tumor microenvironment).”
The study’s findings “showed that inhalation of CBD was able to not only limit the tumor growth but also to alter the dynamics of TME by repressing P-selectin, apelin, and interleukin (IL)-8, as well as blocking a key immune checkpoint-indoleamine 2,3-dioxygenase (IDO).”
In addition, “CBD enhanced the cluster of differentiation (CD) 103 expression, indicating improved antigen presentation, promoted CD8 immune responses, and reduced innate Lymphoid Cells within the tumor.”
The study concludes by stating that “Overall, our novel findings support the possible therapeutic role of inhaled CBD as an effective, relatively safe, and easy to administer treatment adjunct for GBM with significant impacts on the cellular and molecular signaling of TME, warranting further research.”
For more information on this study, including a look at the full abstract, you can click here.